Search results
Results from the WOW.Com Content Network
Discoid lupus erythematosus (DLE) is an uncommon autoimmune disease of the basal cell layer of the skin. It occurs in humans [1] and cats, more frequently occurring in dogs. It was first described in dogs by Griffin and colleagues in 1979. [2] [3] DLE is one form of cutaneous lupus erythematosus (CLE). DLE occurs in dogs in two forms: a ...
Dogs suffering from autoimmune diseases of the skin may experience a variety of symptoms, including persistent itching and scratching, lesions, wounds, blisters, and other skin damage, as well as loss of skin pigment. [5] Two cases of autoimmune diseases that are often found include Discoid lupus erythematosus (DLE) and Pemphigus.
A subset of AHAA appear to mimic the activity of lupus anticoagulant and increase Apo-H binding to phospholipids. [5] These two activities can be differentiated by the binding to Apo-H domains, whereas binding to the 5th domain promotes that anti-coagulant activity binding to the more N-terminal domains promotes lupus anticoagulant-like activities.
There appears to be a genetic basis for the disease. [85] Discoid lupus erythematosus is an uncommon autoimmune disease of the skin in dogs. It does not progress to systemic lupus erythematosus in dogs. The most common initial symptom is scaling and loss of pigment on the nose. [34]
Treatment for a lupus anticoagulant is usually undertaken in the context of documented thrombosis, such as extremity phlebitis or dural sinus vein thrombosis. Patients with a well-documented (i.e., present at least twice) lupus anticoagulant and a history of thrombosis should be considered candidates for indefinite treatment with anticoagulants.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The total cost for the first year of treatment with belimumab is $28,000. [38] Belimumab is much more expensive than other drugs used to treat lupus, including prednisone ($140 per year), hydroxychloroquine ($132), oral methotrexate ($432), azathioprine ($468), and mycophenolate mofetil ($1,224).
Undifferentiated connective tissue disease (UCTD) (also known as latent lupus or incomplete lupus [1]) is a disease in which the connective tissues are targeted by the immune system. It is a serological and clinical manifestation of an autoimmune disease .